Kearney, NE., - SCORR Marketing, a global health science marketing and communications firm, in association with Applied Clinical Trials, has released the results of a comprehensive survey on the use of paperless processes in clinical trials. The report describes which paperless processes have largely been implemented and the biggest benefits that have been realized. It also pinpoints which stakeholders are most reluctant to implement paper processes and forecasts what the future holds for these processes. “In the survey, we discovered that the users of paperless processes felt strongly that these processes have improved data collection as well as data and document quality,” said Cliff Echols, director of market intelligence at SCORR. “However, some users, particularly those from academic institutions, report that paperless processes haven’t reduced the need for data entry as much as they had hoped.” The survey also gathered information on current levels of paperless data collection, the benefits and challenges stemming from eClinical processes, resistance and hurdles concerning paperless trials and predictions about the future of the practice. Respondents included individuals from across the globe, representing CROs, pharmaceutical companies, academic institutions, consultancies, service providers, research sites, hospitals and medical device companies. “We found that the cost of technology and fear of change were the two greatest hindrances to the adoption of paperless processes,” said Lisa Henderson, editor in chief at Applied Clinical Trials, a part of the life sciences unit of UBM. “However, many respondents, particularly those working within a CRO, believe that there will still be a dramatic increase in their company’s use of paperless processes over the next three years.” Download the full report at scorrmarketing.com. About SCORR Marketing SCORR Marketing is the leading marketing and communications firm in the health sciences industry. We partner with organizations involved in global research, development and commercialization of biopharmaceutical and device products and the delivery of health care products and services. At SCORR, we achieve results for our clients by applying our proven, disciplined approach to synthesize market intelligence, strategy and creativity. We have locations across North America and Europe. For more information, visit www.scorrmarketing.com.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.